Trial Profile
Study ATG115317, a Comparison of Atorvastatin and Glimepiride Fixed Dose Combination and Atorvastatin and Glimepiride Loose Combination in the Treatment of Patients With Type 2 Diabetes Mellitus
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Atorvastatin/glimepiride (Primary) ; Atorvastatin; Glimepiride
- Indications Hypercholesterolaemia; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 31 May 2013 Planned end date changed from 1 Jun 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.
- 31 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 09 Nov 2012 Planned end date changed from 1 Aug 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.